084990.KQ
Helixmith Co., Ltd
KOE · Healthcare · Biotechnology · KR
KRW 2,955.00
+0.34%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.4B | 2.6B | 5.0B | 4.2B | 2.8B |
| Cost of Revenue | 3.7B | 3.4B | 2.1B | 2.1B | 12.8B |
| Gross Profit | (1.3B) | (804.6M) | 2.9B | 2.1B | (10.0B) |
| Operating Expenses | |||||
| R&D Expense | 1.9B | 1.7B | 6.6B | 17.1B | 28.1B |
| SG&A Expense | 4.6B | 3.5B | 6.7B | 10.9B | 23.3B |
| General & Admin Expense | 874.6M | 1.2B | 2.2B | 2.8B | 3.4B |
| Selling & Marketing Expense | 1.8B | 2.3B | 4.4B | 8.1B | 9.4B |
| Other Expenses | 2.2B | 4.0B | 7.5B | 9.3B | (8.8B) |
| Total Operating Expenses | 8.1B | 9.1B | 20.8B | 37.4B | 42.6B |
| Cost and Expenses | 11.8B | 12.5B | 22.9B | 39.4B | 55.4B |
| Operating Income (EBIT) | (9.4B) | (9.9B) | (18.0B) | (35.2B) | (52.6B) |
| Non-Operating | |||||
| Interest Income | 821.0M | 1.1B | 3.7B | 3.2B | 2.3B |
| Interest Expense | 36.3M | 5.7M | 162.3M | 582.4M | 2.1B |
| Net Interest Income | 784.7M | 1.0B | 3.6B | 2.6B | 219.8M |
| Other Non-Op Income/Expense | 7.8B | 9.4B | 2.5B | (29.0B) | 9.6B |
| Non-Operating Income (excl Interest) | (6.9B) | — | (2.6B) | 28.5B | (11.6B) |
| EBT (Pre-Tax Income) | (1.6B) | (460.1M) | (15.5B) | (64.3B) | (43.0B) |
| Income Tax Expense | — | — | — | (100.0M) | 57.5M |
| Bottom Line | |||||
| Net Income | (1.6B) | (434.9M) | (15.5B) | (64.1B) | (43.5B) |
| Earnings from Cont. Ops | (1.6B) | (460.1M) | (15.5B) | (64.2B) | (43.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.6B) | (434.9M) | (15.5B) | (64.1B) | (43.5B) |
| Per Share | |||||
| Basic EPS | (₩35) | (₩9) | (₩329) | (₩1,544) | (₩1,154) |
| Diluted EPS | (₩35) | (₩9) | (₩329) | (₩1,544) | (₩1,154) |
| Revenue Per Share | ₩53 | ₩56 | ₩106 | ₩101 | ₩74 |
| Shares | |||||
| Basic Shares Outstanding | 46.0M | 46.1M | 47.0M | 41.5M | 37.7M |
| Diluted Shares Outstanding | 46.0M | 46.1M | 47.0M | 41.5M | 37.7M |
| Profitability Metrics | |||||
| EBITDA | (6.1B) | (8.1B) | (11.1B) | (53.0B) | (30.5B) |
| D&A | 1.6B | 1.8B | 4.2B | 10.7B | 10.4B |
| EBIT | (7.7B) | (9.9B) | (15.3B) | (63.7B) | (40.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026